In December 2024, the editors of Science handed their Breakthrough of the Year to a molecule most Americans had never heard of. Lenacapavir, a Gilead injection given twice a year, had just done the thing HIV prevention had chased for four decades. In a Phase 3 trial of cisgender women across sub-Saharan Africa, PURPOSE 1, it stopped every infection: zero seroconversions in the injection group, against a background rate that would have produced dozens. A companion trial in gay men and gender-diverse people, PURPOSE 2, logged two infections among 2,179 participants, far below the background infection rate and below the daily-Truvada group it was tested against. At the International AIDS Conference, researchers reported that a year-long extension of both trials held the line: across another twelve months of follow-up, only one participant acquired HIV.
Take the enthusiasm at face value for a moment, because the data earn it. This is as close to a functional HIV vaccine as anything the field has produced, delivered as two shots a year instead of a pill someone has to remember every morning. The field did not reach for its usual caution, and Science does not hand its top prize to incremental results. The molecule works.
So here is the quiet question a veteran learns to ask before the applause dies down: what does it cost, and to whom. Gilead brought lenacapavir to the American market as Yeztugo after the FDA cleared it in June 2025, at a list price of $28,218 a year, which is $14,109 a shot, twice. Set that against what it costs to actually make the drug. Researchers at the University of Liverpool and Howard University worked the ingredient and manufacturing math and found that generic lenacapavir could be produced for $35 to $46 per person per year at a volume of two million patients, falling toward $25 a year at five million. The American price is not a markup in the ordinary sense. It is the cost of the drug multiplied by roughly a thousand.
There is a tidy irony buried in the science itself. The structural-biology work on HIV’s capsid that made this molecule possible did not spring fully formed from a Gilead lab. The preclinical proof that long-acting lenacapavir could block infection at all came out of macaque studies co-funded by the National Institutes of Health, the National Cancer Institute, and the federal government’s Frederick National Laboratory, alongside Gilead itself. American taxpayers helped seed the foundation. American patients get the thousand-fold bill.
The company has an answer for the affordability charge, and it is worth stating fairly. Gilead signed voluntary licenses with three generic manufacturers to supply low-cost lenacapavir, and with backing from the Gates Foundation, Unitaid, and the Global Fund, those generics are slated to reach up to 120 lower-income countries at roughly $40 a year starting in 2027. Near-cost pricing for the poorest countries. It reads well in a press release.
Read the map instead. Andrew Hill, the Liverpool researcher behind the cost analysis, points out that the licensing deal draws a border, and the virus does not respect it. 30 percent of new HIV transmission happens in countries left off Gilead’s list. Much of Latin America, most of Eastern Europe, Central Asia, the Middle East and North Africa are excluded, and those are precisely the regions where the epidemic is now growing fastest. The countries that most need the closest thing to an HIV vaccine cannot buy it at the price that makes it a vaccine. They are quoted the other number.
This is where the celebration and the ledger stop lining up. The prevention signal is extraordinary and it is not in dispute; the access regime is a choice, and it was made in a boardroom. A drug does not become a blockbuster by selling at $40. It becomes one by charging $28,218 in the rich markets and letting philanthropy and the US government backfill the rest. The State Department has already pledged PEPFAR money to reach up to two million people abroad by 2028, which is to say the American taxpayer is on the hook twice: once for the basic research, and again to buy the finished product for everyone the list price prices out.
The absurdity has a clean expression. On the current American math, as one clinical bulletin dryly noted, it now appears cheaper to become HIV positive and take lifelong treatment than to take lenacapavir and stay negative. Prevention, the thing the whole health system claims to want, costs more than the disease. Winnie Byanyima, who runs UNAIDS, put the same point without the arithmetic: if this game-changing medicine remains unaffordable, it will change nothing.
Two trials and a year of extension proved the molecule can drive HIV infections to nearly zero. That was the hard part, the part that took the structural biology and the decades and the public money, and it is done. The one variable those trials could not touch, the single number standing between a near-perfect result and an actual end to the epidemic, is the one Gilead controls entirely, by itself, in a room with no scientists in it.
Sources
- MedPage Today – Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year (IAC)
- New England Journal of Medicine – PURPOSE 2: Twice-Yearly Lenacapavir in Men and Gender-Diverse Persons
- New England Journal of Medicine – PURPOSE 1: Twice-Yearly Lenacapavir or Daily F/TAF in Cisgender Women
- HIV i-Base – Long-acting injectable PrEP approved in the US: priced at $28,000 a year
- IDSA – HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price
- EATG / IDWeek 2025 – Reduced pricing for lenacapavir is possible and profitable (Hill analysis, excluded regions)
- Fierce Pharma – Generics makers to sell Gilead’s Yeztugo at $40 a year under Gates Foundation deals
- Science – 2024 Breakthrough of the Year: a new era of HIV prevention
- U.S. Department of State – PEPFAR support to reach up to 2 million people with lenacapavir by 2028
- eBioMedicine – Long-acting lenacapavir protects macaques against simian-tropic HIV (NIH/NCI co-funded preclinical work)